Market Research Logo

PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025

Summary

Neisseria meningitidis is a Gram-negative, encapsulated diplococcal bacterium and is the causative agent for invasive meningococcal disease. Although relatively rare around the globe, invasive meningococcal disease is widely feared because of its high mortality rate even in otherwise healthy individuals. The onset of invasive meningococcal disease typically begins within three to seven days of infection, but can occur as early as one day after infection. If left untreated, meningococcal disease progresses rapidly. Even with appropriate treatment, up to 10% of all cases still result in death within 24 to 48 hours of symptom onset. This rapid onset and progression of the disease emphasizes the need for a prophylactic approach by vaccination.

Pharmaceutical companies have developed vaccines addressing the most urgent medical needs based on clinical efficacy and epidemiology. The resulting vaccines can be divided into three categories, although other and finer segmentations can be made. These three categories include monovalent vaccines targeting serogroup C (MenC vaccines), vaccines protecting against most serogroup B strains (MenB vaccines), and tetravalent vaccines protecting against serogroups A, C, W, and Y (MenACWY vaccines). While the MenB vaccines use recombinant proteins as antigens, all other meningococcal vaccines are based on the polysaccharide capsules of the various serogroups.

Highlights

Key Questions Answered

  • Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the meningococcal vaccine marketplace.
  • What will be the effect of recent and upcoming changes in national immunization schedules?
  • How will the new first-in-class vaccine covering all main serogroups (MenABCWY) be received in the different markets?
  • What research and development (R&D) strategies will companies leverage to compete in the future meningococcal vaccine marketplace?
  • Which patient population(s) are most likely to be targeted for vaccines against serogroup B and the pentavalent MenABCWY pipeline vaccine?
Key Findings
  • GlobalData projects the meningococcal vaccine market in the US, 5EU, Japan, and Brazil to grow from approximately $1.1bn in 2015 to $1.8bn in 2025, at a compound annual growth rate (CAGR) of 5.4%. This growth across the 8MM will primarily be driven by the introduction of additional meningococcal vaccines into the national routine infant and adolescent vaccination schedules in some 5EU countries. Further growth will be the result of the launch of a pentavalent MenABCWY vaccine during the forecast period while the commercial meningococcal vaccine markets in Brazil and Japan will experience a decline at a negative CAGR of 1.8% and 0.9% respectively.
  • With most countries in the 8MM using serogroup B vaccines only for individuals at high risk of contracting meningococcal disease, the routine application of these protein-based vaccines is seen as the major unmet need to be addressed in the oncoming years.
  • GlobalData anticipates that opportunities will center on the improvement of vaccine long-term efficacy whilst addressing the cost effectiveness concerns voiced by various governmental institutions.
Scope
  • Overview of meningococcal disease, including epidemiology, etiology, pathophysiology, regional serogroup distribution, as well current routine meningococcal vaccine recommendations of all 8MM covered.
  • Topline meningococcal vaccine market revenue from 2015-2025. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the meningococcal vaccine market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
  • Analysis of the current and future market competition in the global meningococcal vaccine marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global meningococcal vaccine market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the meningococcal vaccine market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Introduction
3.2 Etiology and Pathophysiology
3.2.1 Etiology
3.2.2 Pathophysiology
3.3 Symptoms
3.4 Prognosis
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and morbidities
4.3 Global Trends
4.3.1 US
4.3.2 5EU
4.3.3 Japan and Brazil
4.4 Forecast Methodology
4.4.1 Sources Used Tables
4.4.2 Forecast Assumptions and Methods
4.4.3 Sources Not Used
4.5 Epidemiological Forecast for IMD (2015-2025)
4.5.1 All IMD Combined
4.5.2 Laboratory-Confirmed Incident Cases of Serogroup B IMD
4.5.3 Laboratory-Confirmed Incident Cases of Serogroup C IMD
4.5.4 Laboratory-Confirmed Incident Cases of Serogroup Y IMD
4.5.5 Laboratory-Confirmed Incident Cases of Other Serogroup IMD
4.5.6 Distribution of Serogroups
4.5.7 US College Freshmen
4.6 Discussion
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Disease Management
5.1 Meningococcal Immunization Policy
5.1.1 Routine Immunization Recommendations and Most Frequently Administered Meningococcal Vaccines
5.2 US
5.2.1 Immunization Recommendations
5.2.2 Clinical Practice
5.3 France
5.3.1 Immunization Recommendations
5.3.2 Clinical Practice
5.4 Germany
5.4.1 Immunization Recommendations
5.4.2 Clinical Practice
5.5 Italy
5.5.1 Immunization Recommendations
5.5.2 Clinical Practice
5.6 Spain
5.6.1 Immunization Recommendations
5.6.2 Clinical Practice
5.7 UK
5.7.1 Immunization Recommendations
5.7.2 Clinical Practice
5.8 Japan
5.9 Brazil
5.9.1 Immunization Recommendations
5.9.2 Clinical Practice
6 Competitive Assessment
6.1 Overview
6.2 Product Profiles - MenACWY Vaccines
6.2.1 Menactra
6.2.2 Menveo
6.2.3 Nimenrix
6.3 Product Profiles - MenB Vaccines
6.3.1 Bexsero
6.3.2 Trumenba
6.4 Product Profiles - MenC Vaccines
6.4.1 NeisVac-C
6.4.2 Menjugate
6.4.3 Menitorix
6.5 Other Meningococcal Vaccines
6.5.1 Overview
7 Unmet Needs and Opportunities
7.1 Overview
7.2 A Safe and Effective Universal Meningococcal Vaccine
7.2.1 Unmet Need
7.2.2 Gap Analysis
7.2.3 Opportunity
7.3 Long-Term Protection Against Invasive Meningococcal Disease
7.3.1 Unmet Need
7.3.2 Gap Analysis
7.3.3 Opportunity
7.4 Improvements in Clinical Trial Design
7.4.1 Unmet Need
7.4.2 Gap Analysis
7.4.3 Opportunity
7.5 Improved Vaccine Cost Effectiveness
7.5.1 Unmet Need
7.5.2 Gap Analysis
7.5.3 Opportunity
7.6 A Prenatal Meningococcal Vaccine
7.6.1 Unmet Need
7.6.2 Gap Analysis
7.6.3 Opportunity
7.7 Reducing Vaccination Frequency in Infants
7.7.1 Unmet Need
7.7.2 Gap Analysis
7.7.3 Opportunity
7.8 Enhanced Education and Awareness of the General Population
7.8.1 Unmet Need
7.8.2 Gap Analysis
7.8.3 Opportunity
8 Pipeline Assessment
8.1 Overview
8.2 Clinical Trial Mapping and Future Trends
8.2.1 Clinical Trials by Status
8.2.2 Clinical Trials by Pipeline Vaccine
8.2.3 Future Clinical Trial Design Considerations
8.3 Promising Vaccines in Clinical Development
8.3.1 MenABCWY
8.3.2 Men Quad TT
8.3.3 Brazil MenC Vaccine
8.4 Promising Early-Stage Pipeline Products
9 Current and Future Players
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
9.3.1 GlaxoSmithKline
9.3.2 Sanofi
9.3.3 Pfizer
10 Market Outlook
10.1 Global Markets
10.1.1 Forecast
10.1.2 Drivers and Barriers - Global Issues
10.2 United States
10.2.1 Forecast
10.2.2 Key Events
10.2.3 Drivers and Barriers
10.3 5EU
10.3.1 5EU
10.3.2 France
10.3.3 Germany
10.3.4 Italy
10.3.5 Spain
10.3.6 UK
10.4 Japan
10.4.1 Forecast
10.4.2 Key Events
10.4.3 Drivers and Barriers
10.5 Brazil
10.5.1 Forecast
10.5.2 Key Events
10.5.3 Drivers and Barriers
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.4.1 Vaccine Coverage
11.4.2 Vaccine Approval vs. Routine Schedule Inclusion
11.4.3 Vaccines Included
11.4.4 Key Launch Dates
11.4.5 General Pricing Assumptions
11.4.6 Individual Vaccine Assumptions
11.4.7 Pricing of Pipeline Agents
11.5 Primary Research - KOLs Interviewed for this Report
11.6 Primary Research - Prescriber Survey
11.7 About the Authors
11.7.1 Analyst
11.7.2 Therapy Area Director
11.7.3 Epidemiologist
11.7.4 Managing Epidemiologist
11.7.5 Global Director of Therapy Analysis and Epidemiology
11.7.6 Global Head of Healthcare
11.8 About GlobalData
11.9 Disclaimer
1.1 List of Tables
Table 1: Symptoms of Meningococcal Disease
Table 2: Risk Factors and Comorbidities for IMD
Table 3: 8MM, Sources of Laboratory-Confirmed IMD Incidence
Table 4: 8MM, Sources of Laboratory-Confirmed Serogroup B IMD Incidence
Table 5: 8MM, Sources of Laboratory-Confirmed Serogroup C IMD Incidence
Table 6: 8MM, Sources of Laboratory-Confirmed Serogroup Y IMD Incidence
Table 7: 8MM, Sources of Laboratory-Confirmed Other Serogroup IMD Incidence (Includes Serogroups A, W, X, and All Others)
Table 8: 5EU, Japan, and Brazil Sources of Laboratory-Confirmed Serogroup W IMD Incidence
Table 9: Germany, Italy, and Brazil, Sources of Laboratory-Confirmed Serogroup A IMD Incidence
Table 10: College Freshmen Residing in Campus Accommodation
Table 11: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
Table 12: 8MM and Japan, Age-specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015
Table 13: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015
Table 14: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N (Row %), 2015
Table 15: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
Table 16: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
Table 17: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
Table 18: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
Table 19: College Freshmen in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025
Table 20: National Immunization Recommendation Agencies, 2016
Table 21: National Immunization Recommendations for Meningococcal Vaccines, 2016
Table 22: Most Frequently Administered Meningococcal Vaccines in the Global Markets, 2015
Table 23: Country Profile - US
Table 24: Country Profile - France
Table 25: Country Profile - Germany
Table 26: Country Profile - Italy
Table 27: Country Profile - Spain
Table 28: Country Profile - UK
Table 29: Country Profile - Japan
Table 30: Country Profile - Brazil
Table 31: Leading Vaccines Against Meningococcal Disease, 2015
Table 32: Product Profile - Menactra
Table 33: Efficacy of Menactra for Individuals Receiving Either One- or Two-Dose Regimens
Table 34: Safety of Menactra for Individuals Receiving One Dose of Menactra
Table 35: Menactra SWOT Analysis, 2016
Table 36: Global Sales Forecast ($m) for Menactra, 2015-2025
Table 37: Product Profile - Menveo
Table 38: Efficacy of Menveo
Table 39: Safety of Menveo
Table 40: Menveo SWOT Analysis, 2016
Table 41: Global Sales Forecasts ($m) for Menveo, 2015-2025
Table 42: Product Profile - Nimenrix
Table 43: Efficacy of Nimenrix
Table 44: Safety of Nimenrix
Table 45: Nimenrix SWOT Analysis, 2016
Table 46: Global Sales Forecast ($m) for Nimenrix, 2015-2025
Table 47: Product Profile - Bexsero
Table 48: Efficacy of Bexsero
Table 49: Safety of Bexsero
Table 50: Bexsero SWOT Analysis, 2016
Table 51: Global Sales Forecasts ($m) for Bexsero, 2015-2025
Table 52: Product Profile - Trumenba
Table 53: Efficacy of Trumenba
Table 54: Safety of Trumenba
Table 55: Trumenba SWOT Analysis, 2016
Table 56: Global Sales Forecasts ($m) for Trumenba, 2015-2025
Table 57: Product Profile - NeisVac-C
Table 58: Efficacy of NeisVac-C
Table 59: Safety of NeisVac-C
Table 60: NeisVac-C SWOT Analysis, 2016
Table 61: Global Sales Forecasts ($m) for NeisVac-C, 2015-2025
Table 62: Product Profile - Menjugate
Table 63: Efficacy of Menjugate
Table 64: Safety of Menjugate
Table 65: Menjugate SWOT Analysis, 2016
Table 66: Global Sales Forecasts ($m) for Menjugate, 2015-2025
Table 67: Product Profile - Menitorix
Table 68: Efficacy of Menitorix
Table 69: Safety of Menitorix
Table 70: Menitorix SWOT Analysis, 2016
Table 71: Global Sales Forecasts ($m) for Menitorix, 2015-2025
Table 72: Other Meningococcal Vaccines
Table 73: Unmet Needs and Opportunities for Meningococcal Vaccines
Table 74: Product Profile - MenABCWY
Table 75: Immunogenicity of MenABCWY
Table 76: MenABCWY SWOT Analysis, 2016
Table 77: Global Sales Forecast ($m) for MenABCWY, 2015-2025
Table 78: Product Profile - Men Quad TT
Table 79: Men Quad TT SWOT Analysis, 2016
Table 80: Global Sales Forecasts ($m) for Men Quad TT, 2015-2025
Table 81: Product Profile - Brazil’s MenC
Table 82: Brazil MenC SWOT Analysis, 2016
Table 83: Global Sales Forecast ($m) for Brazil’s MenC, 2015-2025
Table 84: Important Meningococcal Vaccines in Development, 2016
Table 85: Key Companies in the Meningococcal Vaccine Market in the 8MM, 2016
Table 86: GSK’s Meningococcal Vaccines Portfolio Assessment, 2016
Table 87: GSK SWOT Analysis in Meningococcal Vaccines, 2016
Table 88: Sanofi’s Meningococcal Vaccines Portfolio Assessment, 2016
Table 89: Sanofi SWOT Analysis in Meningococcal Vaccines, 2016
Table 90: Pfizer’s Meningococcal Vaccines Portfolio Assessment, 2016
Table 91: Pfizer SWOT Analysis in Meningococcal Vaccines, 2016
Table 92: Global Sales Forecasts ($m) for Meningococcal Vaccines, 2015-2025
Table 93: 8MM Meningococcal Vaccines Market - Drivers and Barriers, 2015-2025
Table 94: US Sales Forecast ($m) for Meningococcal Vaccines, 2015‒2025
Table 95: Key Events Impacting Sales for Meningococcal Disease in the US, 2015‒2025
Table 96: US Meningococcal Vaccines Market - Drivers and Barriers, 2015‒2025
Table 97: 5EU Sales Forecasts ($m) for Meningococcal Vaccines, 2015‒2025
Table 98: 5EU Meningococcal Vaccines Market - Drivers and Barriers, 2015‒2025
Table 99: France Sales Forecast ($m) for Meningococcal Vaccines, 2015‒2025
Table 100: Key Events Impacting Sales for Meningococcal Vaccines in France, 2015‒2025
Table 101: France Meningococcal Vaccines Market - Drivers and Barriers, 2015‒2025
Table 102: Sales Forecast ($m) for Meningococcal Vaccines in Germany, 2015‒2025
Table 103: Key Events Impacting Sales for Meningococcal Disease in Germany, 2015‒2025
Table 104: Germany Meningococcal Vaccines market - Drivers and Barriers, 2015‒2025
Table 105: Italy Sales Forecasts ($m) for Meningococcal Vaccines, 2015‒2025
Table 106: Key Events Impacting Sales for Meningococcal Disease in Italy, 2015‒2025
Table 107: Italy Meningococcal Vaccines Market - Drivers and Barriers, 2015‒2025
Table 108: Spain Sales Forecast ($m) for Meningococcal Vaccines, 2015‒2025
Table 109: Key Events Impacting Sales for Meningococcal Vaccines in Spain, 2015‒2025
Table 110: Spain Meningococcal Vaccines Market - Drivers and Barriers, 2015‒2025
Table 111: UK Sales Forecast ($m) for Meningococcal Vaccines, 2015‒2025
Table 112: Key Events Impacting Sales for Meningococcal Disease in the UK, 2015‒2025
Table 113: UK Meningococcal Vaccines market - Drivers and Barriers, 2015‒2025
Table 114: Japan Sales Forecasts ($m) for Meningococcal Vaccines, 2015‒2025
Table 115: Key Events Impacting Sales for Meningococcal Vaccines in Japan, 2015‒2025
Table 116: Japan Meningococcal Vaccines Market - Drivers and Barriers, 2015‒2025
Table 117: Brazil Sales Forecasts ($m) for Meningococcal Vaccines, 2015‒2025
Table 118: Key Events Impacting Sales for Meningococcal Disease in Brazil, 2015‒2025
Table 119: Brazil Meningococcal Vaccines Market - Drivers and Barriers, 2015‒2025
Table 120: Key Launch Dates
Table 121: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Membrane Structure of N. meningitidis
Figure 2: Genetic Clusters for Polysaccharide Capsules
Figure 3: Laboratory-Confirmed Incidence of IMD in the EU, All Ages, Both Sexes, 2000-2014
Figure 4: 8MM, Laboratory-Confirmed Incident Cases of all IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
Figure 5: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, 2015
Figure 6: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, 2015
Figure 7: 8MM, Age-Standardized Laboratory-Confirmed Incidence (Cases per 100,000 Population) of IMD, All Ages, by Sex, 2015
Figure 8: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
Figure 9: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
Figure 10: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
Figure 11: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
Figure 12: 8MM, Serogroup Distribution of Laboratory-Confirmed Incident IMD Cases, %, 2015
Figure 13: 8MM, Serogroup Distribution of Laboratory-Confirmed Incident IMD Cases, %, 2025
Figure 14: College Freshmen Living in Campus Accommodation in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025
Figure 15: National Immunization Schedule for Meningococcal Vaccines across the 8MM
Figure 16: Meningococcal Vaccines - Key Clinical Trial Landscape, 2016
Figure 17: Meningococcal Vaccines - Phase II/III Pipeline, 2016
Figure 18: Competitive Assessment of Late-Stage Pipeline Meningococcal Vaccines, 2015-2025
Figure 19: Clinical and Commercial Positioning of MenABCWY
Figure 20: Clinical and Commercial Positioning of Men Quad TT
Figure 21: Clinical and Commercial Positioning of Brazil’s MenC
Figure 22: Global Sales of Branded Vaccines for Meningococcal Disease by Company, 2015-2025
Figure 23: Company Portfolio Gap Analysis in Meningococcal Vaccines, 2015-2025
Figure 24: Annual Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
Figure 25: Global Sales for Meningococcal Vaccines by Region, 2015 and 2025
Figure 26: US Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
Figure 27: Sales of Meningococcal Vaccines by Type of Vaccine in the 5EU in 2015 and 2025
Figure 28: France Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
Figure 29: Germany Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
Figure 30: Italy Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
Figure 31: Spain Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
Figure 32: UK Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
Figure 33: Japan Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025
Figure 34: Brazil Sales of Meningococcal Vaccines by Type of Vaccine in 2015 and 2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report